Market Cap: $9.44B
KI
Krystal Biotech, Inc.
KRYS
NASDAQ (NASDAQ Global Market)USD
Market Cap: $9.44B
Krystal Biotech's Insider Trading Raises Questions on Strategic Decisions In a noteworthy development for Krystal Biotech, a prominent player in the biotechnology sector, board member Rossi has execut…
### Insights into Insider Activity at Krystal Biotech Krystal Biotech, a key player in the biotechnology sector, experiences notable insider trading activity that attracts attention from both investor…
Strategic Insider Transactions: A Glimpse into Krystal Biotech’s Corporate Dynamics In a noteworthy shift within Krystal Biotech, a prominent insider transaction has recently come to light. Board memb…
Analyst signal flags clinical and regulatory uncertainty at Krystal Biotech Nine analysts issue ratings on Krystal Biotech over the past three months, producing a mixed set of views that underscore un…
Nine-Analyst Snapshot Spotlights Clinical Uncertainty Analyst Divergence Mirrors Clinical and Regulatory Risks A nine-analyst sample of coverage on Krystal Biotech is producing a split set of views th…
Krystal Biotech Sees Shift in Market Sentiment Amid Decrease in Short Interest Krystal Biotech Inc. is witnessing a significant decline in short interest, a development that reflects changing market p…
Krystal Biotech's Innovative Approach to Gene Therapy Krystal Biotech, a leading player in the biotechnology sector, focuses on developing innovative gene therapies for patients with rare skin disease…
Krystal Biotech: Advancing Gene Therapy for Skin Diseases Krystal Biotech is at the forefront of innovating gene therapies, specifically targeting skin diseases like dystrophic epidermolysis bullosa (…
Krystal Biotech Faces Mixed Analyst Perspectives Amid Innovations Krystal Biotech, a pioneer in gene therapy technologies, stands at a crucial juncture as it garners evaluations from nine analysts, re…
Krystal Biotech: Navigating Diverse Analyst Perspectives Amidst Innovation Krystal Biotech, a leader in gene therapy, finds itself at a crossroads as nine analysts weigh in on its performance and futu…
Krystal Biotech Faces Increased Short Interest Amid Market Sentiment Krystal Biotech Inc. experiences a notable rise in short interest, reflecting a shift in investor sentiment towards the company. As…
Krystal Biotech Faces Increased Investor Skepticism Amid Rising Short Interest Krystal Biotech Inc. is currently navigating a challenging investor landscape as it experiences a notable rise in short i…
Krystal Biotech Advances Gene Therapy Solutions Amid Market Volatility Krystal Biotech, a leader in gene therapy solutions, continues to make strides in the biotechnology sector, focusing on innovativ…
Krystal Biotech Advances in Gene Therapy for Rare Skin Disorders Krystal Biotech, a leader in the field of gene therapy, continues to make significant strides in developing innovative treatments for r…
Krystal Biotech Gains FDA Approval for Vyjuvek, Transforming Treatments for Rare Skin Disorder Krystal Biotech, Inc. achieves a significant milestone with the FDA's recent approval of an updated label…
FDA Approval Marks a Milestone for Krystal Biotech's Gene Therapy Vyjuvek The U.S. Food and Drug Administration (FDA) has recently granted approval for Krystal Biotech, Inc.'s updated label for its ge…
Krystal Biotech Secures FDA Approval for Vyjuvek, Advancing Gene Therapy for Rare Skin Disorder In a significant development for the field of gene therapy, Krystal Biotech, Inc. receives FDA approval…
Krystal Biotech Faces Diverging Analyst Views Amidst Innovative Therapy Development In the ever-evolving biotechnology sector, Krystal Biotech (KRYS) stands at a crossroads, with analysts expressing a…
Krystal Biotech Faces Diverse Analyst Opinions Amid Innovative Developments Krystal Biotech is currently at a pivotal point in its growth trajectory within the biotechnology sector, as evidenced by th…
Krystal Biotech Prepares for Strategic Earnings Announcement As Krystal Biotech approaches the release of its quarterly earnings report on August 4, 2025, the biopharmaceutical company stands at a cri…
Krystal Biotech Prepares for Insightful Earnings Report Amidst Industry Competition Krystal Biotech is set to release its quarterly earnings report on August 4, 2025, which is anticipated to reveal cr…
Krystal Biotech Gears Up for Significant Quarterly Earnings Report Krystal Biotech, a prominent player in the biopharmaceutical sector, prepares to release its quarterly earnings report on August 4, 2…
Assessing Analyst Perspectives on Krystal Biotech’s Future In the recent months, Krystal Biotech (KRYS) finds itself at the center of attention among market analysts, who provide varied perspectives o…
Krystal Biotech: Navigating a Complex Landscape in the Biopharmaceutical Sector In the dynamic world of biopharmaceuticals, Krystal Biotech finds itself under the scrutiny of 12 analysts who have rece…
Krystal Biotech: Navigating Analyst Perspectives Amidst Uncertainty in the Biopharmaceutical Sector In the past three months, analysts have scrutinized Krystal Biotech (KRYS), delivering a spectrum of…